AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

01/10 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
18/09/26	EUR 0.7110	0.00%
17/09/26	EUR 0.7110	+0.71%
16/09/26	EUR 0.7060	-1.53%
15/09/26	EUR 0.7170	-1.24%
14/09/26	EUR 0.7260	+2.83%

Delayed Quote Deutsche Boerse AG

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Tradegate 04:04:03 21/09/26 pm AEST			5-day change	1st Jan Change
0.7100 ^EUR	-0.14%		+0.71%	-47.87%

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement

Market Cap	56.41M 64.69M 53.26M 48.37M 90.62M 6.21B 91M 638M 246M 3.16B 243M 238M 10.15B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	56.41M 64.69M 53.26M 48.37M 90.62M 6.21B 91M 638M 246M 3.16B 243M 238M 10.15B	EV / Sales 2026 *	47x	EV / Sales 2027 *	43.4x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	AB	Real-time
London S.E.	0Q77	Delayed
CBOE	ABp	Real-time
Tradegate	A8D	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Börse Stuttgart	A8D	Delayed
Boerse Muenchen	A8D	Real-time

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
11/07	AB Science streamlines its portfolio and refocuses on two molecules
11/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Stock Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
05/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
11/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

25/08	AB Science : Franchissement de seuils et déclaration d'intention
17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 day	-0.14%
1 week	+0.71%
Current month	-0.84%
1 month	+1.43%
3 months	-16.35%
6 months	-41.43%
Current year	-47.87%

1 week	0.71	0.72
1 month	0.67	0.74
Current year	0.52	1.55
1 year	0.52	1.55
3 years	0.52	3.71
5 years	0.52	13.81
10 years	0.52	20.1

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-0.14%	+0.71%	-	-	64.69M
MERCK & CO., INC.	-0.19%	+2.04%	+80.19%	+36.87%	362B
MERCK KGAA	-1.22%	-1.22%	+19.95%	-19.05%	64.74B
HALOZYME THERAPEUTICS, INC.	+2.53%	+4.90%	+44.52%	+183.96%	12.76B
KYOWA KIRIN CO., LTD.	-0.29%	+2.94%	-4.00%	-15.43%	7.53B
SK BIOPHARMACEUTICALS CO., LTD.	-1.89%	-2.14%	-31.54%	-12.10%	4.38B
YUHAN CORPORATION	-2.06%	-4.41%	-36.00%	+6.54%	4.08B
BETTA PHARMACEUTICALS CO., LTD.	+1.48%	+3.64%	-29.60%	-13.12%	2.96B
SUPERNUS PHARMACEUTICALS, INC.	-2.14%	+0.86%	-8.77%	+51.84%	2.44B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.41%	+1.15%	-23.58%	-34.10%	1.93B
Average	-0.29%	+0.50%	+1.24%	+20.60%	51.46B
Weighted average by Cap.	-0.09%	+1.57%	+65.73%	+30.99%

	2026 *	2027 *
Net sales	1.2M 1.38M 1.13M 1.03M 1.93M 132M 1.94M 13.57M 5.24M 67.14M 5.17M 5.05M 216M	1.3M 1.49M 1.23M 1.11M 2.09M 143M 2.1M 14.7M 5.67M 72.73M 5.6M 5.48M 234M
Net income	-	-
Net Debt	-	-